{"ticker": {"uuid": "d6ceb2ac-945b-4777-99fc-4b3a64951312", "symbol": "LONA", "name": "LeonaBio, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LeonaBio, Inc.(NasdaqCM: LONA) added to Russell 3000E Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOUG1hVzZ5c1pXTVB6NVVoaVJlcnJBaVhqcDFwaTE4YUJ5akRSU2dlSktfX1RhMmVOX2hOQmotMjRZQTVyNzVyRG01UnZORmRmQzYzdGlLc1RqV2FGWUZnWXk0WTZOUzhUWHVBTDRvVVVqQzdsRmxGcE9iRVF5TGdNNTBVOV9sdGJ6UzgtV2k5bVRTMmkxY0QzWHZRUFZ1VjdGMWM2UDJyZW5xdnRY?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNc1EyTVFCVVBtSGQ0VG9tTnY3bVlEV1YxUFZuR2FWVm9QRXBELXZuWV9VZGZLVFpEX0Y0OEUzQmM0U29jYXRfN0hFSWROUmJ0UVVjblJId3p0QXBMRGM5Z3VvMzRfRV9WSmFXU1lQWFZSX082bEtOdXlTTlVMTmZGdV9IZDBzNnNsWWhidko2VTN5bnZva09rREdWc1NidnVhRERjOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63", "summary": "LeonaBio, Inc. Director Callori Fred was granted 56,000 stock options with an exercise price of $9.63 per share, expiring on May 4, 2036. These options will vest monthly in equal installments over 36 months, provided the director continues to serve under the company's 2026 Equity", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-fdec1bb6f6cd.html", "source_name": "Stock Titan", "published_at": "2026-05-08T00:39:13", "published_display": "08 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials", "summary": "LeonaBio (NASDAQ: LONA) reported a widened net loss of $32.9 million for Q1 2026, primarily due to increased R&D expenses for its Phase 3 ELAINE-3 trial for metastatic breast cancer and higher general and administrative costs. Despite the loss, the company is advancing its late-s", "url": "https://www.stocktitan.net/sec-filings/ATHA/8-k-leona-bio-inc-reports-material-event-34dce06fdaab.html", "source_name": "Stock Titan", "published_at": "2026-05-07T19:39:12", "published_display": "07 May 2026 19:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA)", "summary": "LeonaBio, Inc. director John M. Fluke Jr. was granted options to purchase 28,000 shares of common stock. The stock option has an exercise price of $9.54 per share and an expiration date of April 8, 2036. This award, given as compensation, vests in equal monthly installments over ", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-e9eadaafa033.html", "source_name": "Stock Titan", "published_at": "2026-04-14T06:10:19", "published_display": "14 Apr 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (LONA) grants CMO 350,000 options at $9.54", "summary": "LeonaBio, Inc. (LONA) has granted its Chief Medical Officer, Javier San Martin, 350,000 stock options at an exercise price of $9.54 per share. These options, which expire on April 8, 2036, will vest in equal monthly installments over 48 months, contingent on San Martin's continue", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-78884a474c6e.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:39:47", "published_display": "13 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "28,000-share stock option grant to LeonaBio (LONA) director", "summary": "LeonaBio, Inc. director Michael A. Panzara received a compensatory stock option grant for 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. These option shares will vest in equal monthly installments over 24 months, ", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-c224e3654686.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:39:47", "published_display": "13 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "28,000 stock options granted to LeonaBio (LONA) director Kosacz", "summary": "LeonaBio, Inc. director Barbara Kosacz was granted 28,000 stock options with an exercise price of $9.54 per share, expiring on April 8, 2036. The options will vest in equal monthly installments over 24 months, contingent on her continued service as a Service Provider. This is a r", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-09f195cb2105.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:39:47", "published_display": "13 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug", "summary": "LeonaBio (NASDAQ: LONA) reported its full-year 2025 financial results, showing an increase in cash and investments to $88.3 million, largely due to a $90 million private placement. The company's net loss widened to $105.6 million. This financial boost secures funding for its Phas", "url": "https://www.stocktitan.net/sec-filings/ATHA/8-k-leona-bio-inc-reports-material-event-3ffa99c97525.html", "source_name": "Stock Titan", "published_at": "2026-03-26T23:38:51", "published_display": "26 Mar 2026 23:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Athira Pharma (LONA) Stock Price, News & Analysis $LONA", "summary": "Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for neurodegenerative and cognitive disorders. As of May 22, 2026, its stock closed at $10.33, with an average price target of $10.00 from analysts, indicat", "url": "https://www.marketbeat.com/stocks/NASDAQ/LONA/", "source_name": "MarketBeat", "published_at": "2026-02-13T11:08:58", "published_display": "13 Feb 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (Nasdaq:LONA) - Stock Analysis", "summary": "LeonaBio (Nasdaq:LONA) is a clinical-stage biopharmaceutical company focused on neurodegeneration. The company has a market cap of US$52.6m, with its share price being highly volatile over the past 3 months and shareholders experiencing substantial dilution. LeonaBio currently ha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lona/leonabio", "source_name": "Simply Wall St", "published_at": "2026-02-03T00:52:00", "published_display": "03 Feb 2026 00:52", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for LeonaBio, Inc. (LONA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBmWjFZREx5OEpkMlVIeDUyLWVvWVI3dFZFaUVfU2RORmNmejZRMWJCcWI0dDVyM0RUS1o2N3JUNTVEdXdLRmdqak0wR3R6VmFPWGV1QS1MbS1nejA3NDQ5VHJMcG5yVkZQd2xfaXhUckZpVFJ1R3ZCVg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-15T10:53:19+00:00", "published_display": "15 Jan 2026 10:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio, Inc.: Target Price Consensus and Analysts Recommendations | LONA | US04746L2034", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNOEdVWFF0djZ2UTdCWGRrSWxTTU5RSEJLc1FIekliVzF0QnZ4bWRTMlpUVEVEZmJQWWt6enBiQVlsQ01YVTZMbEpqVXN5ajdjSmR3N1VMbms3RzRLMzlhM2hudGNIRl9HYkI4X1ppazVkLUtvTV9wY29IOUZULXBIdXl3?oc=5", "source_name": "marketscreener.com", "published_at": "2026-01-13T05:34:13+00:00", "published_display": "13 Jan 2026 05:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LONA Stock Price and Chart \u2014 NASDAQ:LONA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE44bEtlS0VvX1YtYmpJVkI4T3o3VVR6eVkyVmQzaTc1NXdGenhlUGMzcTNSQ2ZrNXJsaHhwQnBWXzFvVl80blhCSkpNNFR4UVJYRVNxN2JkVWNZZTJO?oc=5", "source_name": "TradingView", "published_at": "2026-01-12T15:28:10+00:00", "published_display": "12 Jan 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATHA Stock Price, News & Analysis", "summary": "Athira Pharma (ATHA) has rebranded to LeonaBio, Inc. with a new ticker symbol \"LONA,\" focusing on developing novel therapeutics for treatment-resistant metastatic breast cancer and ALS. The company's lead drug candidates are lasofoxifene, currently in a Phase 3 trial for breast c", "url": "https://www.stocktitan.net/overview/ATHA/", "source_name": "Stock Titan", "published_at": "2026-01-09T15:40:31", "published_display": "09 Jan 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker \u201cLONA\u201d", "summary": "Athira Pharma has officially changed its name to LeonaBio, Inc. and will trade under the new ticker symbol \"LONA\" on The Nasdaq Capital Market starting January 12, 2026. This rebranding follows the acquisition of rights to develop lasofoxifene, a Phase 3 asset for metastatic brea", "url": "https://www.globenewswire.com/news-release/2026/01/09/3216018/0/en/athira-pharma-announces-name-change-to-leonabio-inc-with-new-ticker-lona.html", "source_name": "GlobeNewswire", "published_at": "2026-01-09T07:00:00", "published_display": "09 Jan 2026 07:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "LeonaBio, Inc.(NasdaqCM: LONA) added to Russell 3000E Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOUG1hVzZ5c1pXTVB6NVVoaVJlcnJBaVhqcDFwaTE4YUJ5akRSU2dlSktfX1RhMmVOX2hOQmotMjRZQTVyNzVyRG01UnZORmRmQzYzdGlLc1RqV2FGWUZnWXk0WTZOUzhUWHVBTDRvVVVqQzdsRmxGcE9iRVF5TGdNNTBVOV9sdGJ6UzgtV2k5bVRTMmkxY0QzWHZRUFZ1VjdGMWM2UDJyZW5xdnRY?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (NASDAQ: LONA) shareholders approve directors, EY auditor and executive pay cadence", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNc1EyTVFCVVBtSGQ0VG9tTnY3bVlEV1YxUFZuR2FWVm9QRXBELXZuWV9VZGZLVFpEX0Y0OEUzQmM0U29jYXRfN0hFSWROUmJ0UVVjblJId3p0QXBMRGM5Z3VvMzRfRV9WSmFXU1lQWFZSX082bEtOdXlTTlVMTmZGdV9IZDBzNnNsWWhidko2VTN5bnZva09rREdWc1NidnVhRERjOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63", "summary": "LeonaBio, Inc. Director Callori Fred was granted 56,000 stock options with an exercise price of $9.63 per share, expiring on May 4, 2036. These options will vest monthly in equal installments over 36 months, provided the director continues to serve under the company's 2026 Equity", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-fdec1bb6f6cd.html", "source_name": "Stock Titan", "published_at": "2026-05-08T00:39:13", "published_display": "08 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials", "summary": "LeonaBio (NASDAQ: LONA) reported a widened net loss of $32.9 million for Q1 2026, primarily due to increased R&D expenses for its Phase 3 ELAINE-3 trial for metastatic breast cancer and higher general and administrative costs. Despite the loss, the company is advancing its late-s", "url": "https://www.stocktitan.net/sec-filings/ATHA/8-k-leona-bio-inc-reports-material-event-34dce06fdaab.html", "source_name": "Stock Titan", "published_at": "2026-05-07T19:39:12", "published_display": "07 May 2026 19:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA)", "summary": "LeonaBio, Inc. director John M. Fluke Jr. was granted options to purchase 28,000 shares of common stock. The stock option has an exercise price of $9.54 per share and an expiration date of April 8, 2036. This award, given as compensation, vests in equal monthly installments over ", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-e9eadaafa033.html", "source_name": "Stock Titan", "published_at": "2026-04-14T06:10:19", "published_display": "14 Apr 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (LONA) grants CMO 350,000 options at $9.54", "summary": "LeonaBio, Inc. (LONA) has granted its Chief Medical Officer, Javier San Martin, 350,000 stock options at an exercise price of $9.54 per share. These options, which expire on April 8, 2036, will vest in equal monthly installments over 48 months, contingent on San Martin's continue", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-78884a474c6e.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:39:47", "published_display": "13 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "28,000-share stock option grant to LeonaBio (LONA) director", "summary": "LeonaBio, Inc. director Michael A. Panzara received a compensatory stock option grant for 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. These option shares will vest in equal monthly installments over 24 months, ", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-c224e3654686.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:39:47", "published_display": "13 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "28,000 stock options granted to LeonaBio (LONA) director Kosacz", "summary": "LeonaBio, Inc. director Barbara Kosacz was granted 28,000 stock options with an exercise price of $9.54 per share, expiring on April 8, 2036. The options will vest in equal monthly installments over 24 months, contingent on her continued service as a Service Provider. This is a r", "url": "https://www.stocktitan.net/sec-filings/ATHA/form-4-leona-bio-inc-insider-trading-activity-09f195cb2105.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:39:47", "published_display": "13 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug", "summary": "LeonaBio (NASDAQ: LONA) reported its full-year 2025 financial results, showing an increase in cash and investments to $88.3 million, largely due to a $90 million private placement. The company's net loss widened to $105.6 million. This financial boost secures funding for its Phas", "url": "https://www.stocktitan.net/sec-filings/ATHA/8-k-leona-bio-inc-reports-material-event-3ffa99c97525.html", "source_name": "Stock Titan", "published_at": "2026-03-26T23:38:51", "published_display": "26 Mar 2026 23:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Athira Pharma (LONA) Stock Price, News & Analysis $LONA", "summary": "Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for neurodegenerative and cognitive disorders. As of May 22, 2026, its stock closed at $10.33, with an average price target of $10.00 from analysts, indicat", "url": "https://www.marketbeat.com/stocks/NASDAQ/LONA/", "source_name": "MarketBeat", "published_at": "2026-02-13T11:08:58", "published_display": "13 Feb 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio (Nasdaq:LONA) - Stock Analysis", "summary": "LeonaBio (Nasdaq:LONA) is a clinical-stage biopharmaceutical company focused on neurodegeneration. The company has a market cap of US$52.6m, with its share price being highly volatile over the past 3 months and shareholders experiencing substantial dilution. LeonaBio currently ha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lona/leonabio", "source_name": "Simply Wall St", "published_at": "2026-02-03T00:52:00", "published_display": "03 Feb 2026 00:52", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for LeonaBio, Inc. (LONA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBmWjFZREx5OEpkMlVIeDUyLWVvWVI3dFZFaUVfU2RORmNmejZRMWJCcWI0dDVyM0RUS1o2N3JUNTVEdXdLRmdqak0wR3R6VmFPWGV1QS1MbS1nejA3NDQ5VHJMcG5yVkZQd2xfaXhUckZpVFJ1R3ZCVg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-15T10:53:19+00:00", "published_display": "15 Jan 2026 10:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LeonaBio, Inc.: Target Price Consensus and Analysts Recommendations | LONA | US04746L2034", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNOEdVWFF0djZ2UTdCWGRrSWxTTU5RSEJLc1FIekliVzF0QnZ4bWRTMlpUVEVEZmJQWWt6enBiQVlsQ01YVTZMbEpqVXN5ajdjSmR3N1VMbms3RzRLMzlhM2hudGNIRl9HYkI4X1ppazVkLUtvTV9wY29IOUZULXBIdXl3?oc=5", "source_name": "marketscreener.com", "published_at": "2026-01-13T05:34:13+00:00", "published_display": "13 Jan 2026 05:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LONA Stock Price and Chart \u2014 NASDAQ:LONA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE44bEtlS0VvX1YtYmpJVkI4T3o3VVR6eVkyVmQzaTc1NXdGenhlUGMzcTNSQ2ZrNXJsaHhwQnBWXzFvVl80blhCSkpNNFR4UVJYRVNxN2JkVWNZZTJO?oc=5", "source_name": "TradingView", "published_at": "2026-01-12T15:28:10+00:00", "published_display": "12 Jan 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATHA Stock Price, News & Analysis", "summary": "Athira Pharma (ATHA) has rebranded to LeonaBio, Inc. with a new ticker symbol \"LONA,\" focusing on developing novel therapeutics for treatment-resistant metastatic breast cancer and ALS. The company's lead drug candidates are lasofoxifene, currently in a Phase 3 trial for breast c", "url": "https://www.stocktitan.net/overview/ATHA/", "source_name": "Stock Titan", "published_at": "2026-01-09T15:40:31", "published_display": "09 Jan 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker \u201cLONA\u201d", "summary": "Athira Pharma has officially changed its name to LeonaBio, Inc. and will trade under the new ticker symbol \"LONA\" on The Nasdaq Capital Market starting January 12, 2026. This rebranding follows the acquisition of rights to develop lasofoxifene, a Phase 3 asset for metastatic brea", "url": "https://www.globenewswire.com/news-release/2026/01/09/3216018/0/en/athira-pharma-announces-name-change-to-leonabio-inc-with-new-ticker-lona.html", "source_name": "GlobeNewswire", "published_at": "2026-01-09T07:00:00", "published_display": "09 Jan 2026 07:00", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 24, "sentiment_summary": {"positive": 4, "negative": 3, "neutral": 17, "score": 51, "total": 24, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 6.05, "count": 11}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.9, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 9.6, "latest_week": "2026-07-10", "one_week_move": 8.2, "four_week_move": 15.0, "twelve_week_move": 8.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.767067, "market_dynamics_buy_signal": false, "relative_strength": 33.592447, "fair_value_gap": -26.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.393, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.2% over one week, +15.0% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 5}, {"label": "marketscreener.com", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "MarketBeat", "count": 1}, {"label": "Simply Wall St", "count": 1}, {"label": "Zacks Investment Research", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 16}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 11}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "16", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+8.2% over one week, +15.0% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "LeonaBio, Inc.(NasdaqCM: LONA) added to Russell 3000E Index"}], "updated_at": "2026-07-16T06:05:10.828342+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}